BCM
LGND icon

Brasada Capital Management’s Ligand Pharmaceuticals LGND Stock Holding History

Brasada Capital Management’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-4,985
Closed -$514K – 308
2018
Q1 		$514K Sell
4,985
-467
-9% -$46.2K 0.16% 112
2017
Q4 		$466K Buy
+5,452
New +$473K 0.16% 106

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Brasada Capital Management's LGND Position: Q2 2018 in Review

Brasada Capital Management sold out of Ligand Pharmaceuticals (LGND) in Q2 2018, closing a stake of 4,985 shares — an estimated $514K sold.

Brasada Capital Management first reported a position in LGND in Q4 2017 and held it in 2 quarters. The position peaked at $514K in Q1 2018. 346 funds tracked by Wall St. Rank hold LGND as of Q2 2018.

  • Brasada Capital Management reported no remaining Ligand Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
  • Brasada Capital Management sold 4,985 Ligand Pharmaceuticals shares in Q2 2018, an estimated $514K.
  • Brasada Capital Management first reported a position in Ligand Pharmaceuticals in Q4 2017 and held it in 2 quarters.
  • Brasada Capital Management's Ligand Pharmaceuticals position peaked at $514K in Q1 2018.
  • 346 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2018.

Based on Brasada Capital Management's 13F filing for Q2 2018, filed 14 Aug 2018.